Intranasal Ketamine in Treatment-Resistant Depression
This study has been completed.
Information provided by (Responsible Party):
James Murrough, Icahn School of Medicine at Mount Sinai
First received: February 23, 2011
Last updated: December 16, 2016
Last verified: December 2016
The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).
Major Depressive Disorder
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
||Intranasal (IN) Ketamine in Treatment-Resistant Depression (TRD)
Primary Outcome Measures:
- Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: 24 hours ]
Number of patients meeting response criteria of >=50% decrease in MADRS score from baseline , ie, difference in depressive symptoms using MADRS instrument, 24 hours following drug administration
10-item instrument used for the evaluation of depressive symptoms in adults and for the assessment of any changes to those symptoms. Each of the 10 items is rated on a scale of 0 to 6, with differing descriptors for each item. These individual item scores are added together to form a total score, which can range between 0 and 60 points.
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||October 2014 (Final data collection date for primary outcome measure)
Subjects randomized to this arm will receive the active study medication, intranasal ketamine.
A single dose of intranasal ketamine up to 50 mg
Placebo Comparator: Placebo
Subjects randomized to this arm will receive intranasal saline.
Single dose of saline intranasal
|Ages Eligible for Study:
||21 Years to 65 Years (Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Male or female patients, 21-65 years;
- Women of childbearing potential must agree to use a medically accepted means of contraception for the duration of the study;
- Primary diagnosis of major depressive disorder as assessed by the SCID-P;
- Current depressive episode;
- History of a failure to respond to at least one (1) adequate pharmacotherapy trials in the current major depressive episode;
- Subjects must have scored ≥ 30 on the IDS-C30 at Screening ≥ 24 at Treatment Day #1 and #2;
- Each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document;
- Subjects must be able to identify a family member, physician, or friend who will participate in the Treatment Contract and serve as an emergency contact.
- Women who plan to become pregnant, are pregnant or are breast-feeding;
- Any unstable medical illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease;
- Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG;
- Lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, OCD, mental retardation, pervasive developmental disorders, or Tourette's syndrome;
- Drug or alcohol abuse or dependence within the preceding 6 months;
- Lifetime abuse or dependence on ketamine or phencyclidine;
- Patients judged by study investigator to be at high risk for suicide.
- Previous participation in a ketamine study at Mount Sinai
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01304147
|Icahn School of Medicine at Mount Sinai
|New York City, New York, United States, 10029 |
||James W Murrough, MD
||Icahn School of Medicine at Mount Sinai
||James Murrough, Principal Investigator, Icahn School of Medicine at Mount Sinai
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 23, 2011
|Results First Received:
||April 18, 2016
||December 16, 2016
Keywords provided by James Murrough, Icahn School of Medicine at Mount Sinai:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 25, 2017
Depressive Disorder, Major
Depressive Disorder, Treatment-Resistant
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Molecular Mechanisms of Pharmacological Action